1. Update on Treating Painful Diabetic Peripheral Neuropathy: A Review of Current US Guidelines with a Focus on the Most Recently Approved Management Options
- Author
-
Mallick-Searle T and Adler JA
- Subjects
neuropathic ,pain ,painful diabetic peripheral neuropathy ,treatment ,guidelines ,diabetic nerve pain ,Medicine (General) ,R5-920 - Abstract
Theresa Mallick-Searle,1,* Jeremy A Adler2,* 1Division Pain Medicine, Stanford Health Care, Redwood City, CA, USA; 2Pacific Pain Medicine Consultants, Encinitas, CA, USA*These authors contributed equally to this workCorrespondence: Jeremy A Adler, Pacific Pain Medicine Consultants, 477 N El Camino Real, Suite B301, Encinitas, CA, 92024, USA, Tel +1 760 753 1104, Fax +1 760 943 6494, Email jadler@pacificpainmed.comAbstract: Painful diabetic peripheral neuropathy (DPN) is a highly prevalent and disabling complication of diabetes that is often misdiagnosed and undertreated. The management of painful DPN involves treating its underlying cause via lifestyle modifications and intensive glucose control, targeting its pathogenesis, and providing symptomatic pain relief, thereby improving patient function and health-related quality of life. Four pharmacologic options are currently approved by the US Food and Drug Administration (FDA) to treat painful DPN. These include three oral medications (duloxetine, pregabalin, and tapentadol extended release) and one topical agent (capsaicin 8% topical system). More recently, the FDA approved several spinal cord stimulation (SCS) devices to treat refractory painful DPN. Although not FDA-approved specifically to treat painful DPN, tricyclic antidepressants, serotonin/norepinephrine reuptake inhibitors, gabapentinoids, and sodium channel blockers are common first-line oral options in clinical practice. Other strategies may be used as part of individualized comprehensive pain management plans. This article provides an overview of the most recent US guidelines for managing painful DPN, with a focus on the two most recently approved treatment options (SCS and capsaicin 8% topical system), as well as evidence for using FDA-approved and guideline-supported drugs and devices. Also discussed are unmet needs for this patient population, and evidence for potential future treatments for painful DPN, including drugs with novel mechanisms of action, electrical stimulation devices, and nutraceuticals.Keywords: neuropathic, pain, painful diabetic peripheral neuropathy, treatment, guidelines, diabetic nerve pain
- Published
- 2024